ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$19.80
+3.56%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$19.33
From 52W high−35.23%
Volume1.30M
Market cap$3.41B
P/E (TTM)8.8x
P/S (TTM)3.0x
Div yield—
Key dataOct 19, 2026
Open
$19.33
From 52W high
−35.23%
Volume
1.30M
Market cap
$3.41B
ValuationView details →
P/E (Fwd)
21.2x
EV/EBITDA
21.8x
P/E (TTM)
8.8x
RSI (14)
30.6
MomentumView details →
1D Return
+3.56%
YTD Return
−27.22%
SummaryUpdated Jun 1, 2026
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a San Diego-based biopharmaceutical company founded in 1993 that specializes in developing and commercializing treatments for central nervous system disorders. The company has evolved from a research-focused organization into a commercial-stage enterprise with two marketed products addressing rare neurological conditions. ACADIA went public in 2004 and has built its business around addressing unmet medical needs in neuropsychiatric and rare disease markets, with a particular focus on conditions affecting vulnerable patient populations including those with Parkinson's disease, Rett syndrome, and other neurological disorders.
Similar companies
Latest newsMore news →
Acadia Pharmaceuticals received a patent allowance for Daybue that extends U.S. protection to March 2041.20d agoThe United States Patent and Trademark Office issued a Notice of Allowance for Acadia Pharmaceuticals' U.S. Patent Application No. 17/590,496 covering weight-banded dosing of trofinetide, extending U.S. patent protections to March 2041.21d agoAcadia Pharmaceuticals reported that its Phase II Alzheimer's psychosis study narrowly missed its primary goal, though 60 mg results support continued Phase III development, sending its stock down 13%.24d ago